Recent Updates
Recently added Catalysts

LY3867070

Phase 1

Healthy | Small molecule | Other |Eli Lilly and Company|Last Updated: Jun 3, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment196
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07021547A Study of LY3867070 in Healthy ParticipantsPHASE1 RECRUITING 196 — — May 27, 2025Aug 1, 2026Jun 3, 20262 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline up to Approximately Week 7

A summary of TEAEs regardless of causality, will be reported in the Reported Adverse Events module

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline up to Approximately Week 7

A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module

Number of Participants with One or More Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline up to Approximately Week 7

A summary of AEs regardless of causality, will be reported in the Reported Adverse Events module

Secondary Endpoints
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3867070
Baseline up to Approximately Week 7
PK: Maximum Concentration (Cmax) of LY3867070
Baseline up to Approximately Week 7
Part B Pharmacodynamic (PD): Change from Baseline in Gene Expression
Baseline up to Approximately Week 6
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
LY3867070 (Part A)EXPERIMENTALSingle-Ascending Dose of LY3867070 administered orally
LY3867070 (Part B)EXPERIMENTALMultiple-Ascending Doses of LY3867070 administered orally
LY3867070 (Part C)EXPERIMENTALMultiple Doses of LY3867070 administered orally
Placebo (Parts A-C)PLACEBO_COMPARATORPlacebo administered orally
LY3867070 (Part D)EXPERIMENTALDrug-Drug Interaction (DDI) administered orally
Interventions
NameTypeDescription
LY3867070DRUGAdministered orally
PlaceboDRUGAdministered orally
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Are overtly healthy as determined by medical evaluation * Part C of the study includes only Japanese and Chinese participants * Have a body weight greater than or equal to 45 kilogram (kg) and also body mass index 18 to 32 kilogram per square meter (kg/m²) inclusive Exclusion...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJun 3, 2026NCT07021547lastUpdatePostDate: changed
LOWJun 3, 2026NCT07021547lastUpdatePostDate: changed
LOWMay 26, 2026NCT07021547primaryCompletionDate: changed
LOWMay 24, 2026NCT07021547studyFirstPostDate: changed